Talk:Chemogenetics

Wiki Education Foundation-supported course assignment

This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): HelinaSaleh. Peer reviewers: Untediousness.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 18:53, 17 January 2022 (UTC)

plans

I am planning to make some changes and update the info on the Chemogenetics Page and I would kindly appreciate your feed back . I have written the preliminary outline below. Thank you .

• Chemogenetics
  • Indicate the difference between optogenetics and chemogenetics ( i.e., Having more spatiotemporal control . ) Explain how the spatiotemporal control is achieved .
  • Explain more about the process of designing DREADDs and retro DREADDS.
• Benefits :
  • Pharmacology and treating different diseases : link the information to the diseases page . The targeted diseases in chemogenetics currently consist of neurodegenerative disorders such as Parkinsons disease and neuropsychological disorders such as addiction and anxiety, depression and Schizophrenia.
  • The advancement of chemogenetics in pain management . ( add osteoarthritis associated pain to the diseases under investigation in this field. )
• Animal Models  :
  • Advancement and limits : explain non primate models used such as rodent models. Discuss the advancement s and limitation of using non human primate models.
• Future Direction :
  • discuss the future directions considered in the literature and how chemogenetics can be incorporated to treat different disorders. HelinaSaleh (talk) 21:24, 11 May 2017 (UTC)
• References so far include :
  1. Galvan, Adriana; Caiola, Michael J.; Albaugh, Daniel L. (2017-02-25). "Advances in optogenetic and chemogenetic methods to study brain circuits in non-human primates". Journal of Neural Transmission: 1–17. doi:10.1007/s00702-017-1697-8. ISSN 0300-9564.
  2. Dobrzanski, Grzegorz; Kossut, Małgorzata (2017-04-01). "Application of the DREADD technique in biomedical brain research". Pharmacological Reports. 69 (2): 213–221. doi:10.1016/j.pharep.2016.10.015.
  3. Bang, Juwon; Kim, Hak Yeong; Lee, Hyosang. "Optogenetic and Chemogenetic Approaches for Studying Astrocytes and Gliotransmitters". Experimental Neurobiology. 25 (5). doi:10.5607/en.2016.25.5.205. PMC 5081467 Freely accessible. PMID 27790055.
  4. Miller, Rachel E.; Ishihara, Shingo; Bhattacharyya, Bula; Delaney, Ada; Menichella, Daniela M.; Miller, Richard J.; Malfait, Anne-Marie (2017-04-01). "Chemogenetic inhibition of pain neurons in a mouse model of osteoarthritis". Arthritis & Rheumatology: n/a–n/a. doi:10.1002/art.40118. ISSN 2326-5205.
  5. Fleury Curado, Thomaz; Fishbein, Kenneth; Pho, Huy; Brennick, Michael; Dergacheva, Olga; Sennes, Luiz U.; Pham, Luu V.; Ladenheim, Ellen E.; Spencer, Richard (2017-03-10). "Chemogenetic stimulation of the hypoglossal neurons improves upper airway patency". Scientific Reports. 7. doi:10.1038/srep44392. ISSN 2045-2322. PMC 5345079 Freely accessible. PMID 28281681.

08:04, 12 May 2017‎ HelinaSaleh (talk)

I recommend starting the article with a clear description of the method. Currently it jumps straight into a comparison with optogenetics and applications, both of which will be easier to read with a bit more description of the method. T.Shafee(Evo&Evo)^talk 10:55, 31 May 2018 (UTC)

In particular, the first sentence (lead sentence) needs to be as clear and succinct as possible. I recommend checking how it is introduced in the published literature. T.Shafee(Evo&Evo)^talk 11:02, 31 May 2018 (UTC)